Flammer syndrome

The new term Flammer syndrome describes a phenotype characterized by the presence of primary vascular dysregulation together with a cluster of symptoms and signs that may occur in healthy people as well as people with disease. Typically, the blood vessels of the subjects with Flammer syndrome react differently to a number of stimuli, such as cold and physical or emotional stress. Nearly all organs, particularly the eye, can be involved. Although the syndrome has some advantages, such as protection against the development of atherosclerosis, Flammer syndrome also contributes to certain diseases, such as normal tension glaucoma. The syndrome occurs more often in women than in men, in slender people than in obese subjects, in people with indoor rather than outdoor jobs, and in academics than in blue collar workers. Affected subjects tend to have cold extremities, low blood pressure, prolonged sleep onset time, shifted circadian rhythm, reduced feeling of thirst, altered drug sensitivity, and increased general sensitivity, including pain sensitivity. The plasma level of endothelin-1 is slightly increased, and the gene expression in lymphocytes is changed. In the eye, the retinal vessels are stiffer and their spatial variability larger; the autoregulation of ocular blood flow is decreased. Glaucoma patients with Flammer syndrome have an increased frequency of the following: optic disc hemorrhages, activated retinal astrocytes, elevated retinal venous pressure, optic nerve compartmentalization, fluctuating diffuse visual field defects, and elevated oxidative stress. Further research should lead to a more concise definition, a precise diagnosis, and tools for recognizing people at risk. This may ultimately lead to more efficient and more personalized treatment.

синдром Фламмера, первичная сосудистая дисрегуляция, спазм сосудов, похолодание конечностей, артериальная гипотония, глаукома нормального давления, шум в ушах, кровоизлияния на диске зрительного нерва, окклюзии вен сетчатки, профилактическая персонализированная медицина, Flammer syndrome, primary vascular dysregulation, vasospasm, cold extremities, systemic hypotension, normal tension glaucoma, tinnitus, optic disc hemorrhages, retinal vein occlusion, predictive preventive personalized medicine

1. Konieczka K., Fränkl S. Primäre vaskuläre Dysregulation und Glaukom. Primary vascular dysregulation and glaucoma. Z Prakt Augenheilkd 2013; 34: 207-215.

2. Konieczka K., Frankl S., Todorova M.G., Henrich P.B. Unstable oxygen supply and glaucoma. Klin Monbl Augenheilkd 2014; 231(2): 121-126. doi: 10.1055/s-0033-1360242.

3. Konieczka K., Choi H.J., Koch S., Schoetzau A., Küenzi D., Kim D.M. Frequency of symptoms and signs of primary vascular dysregulation in Swiss and Korean populations. Klin Monbl Augenheilkd 2014; 231(4): 344-347. doi: 10.1055/s-0034-1368239.

4. Böhler E., Hoefert H.-W. Lexikon der Modernen Krankheiten. Berlin: Medizinisch Wissenschaftliche Verlagsgesellschaft, 2014.

5. Saner H., Wurbel H., Mahler F., Flammer J., Gasser P. Microvasculatory evaluation of vasospastic syndromes. Adv Exp Med Bio 1987; 220: 215-218.

6. Flammer J., Konieczka K., Flammer A.J. The primary vascular dysregulation syndrome: implications for eye diseases. EPMA J 2013; 4(1): 14. doi: 10.1186/1878-5085-4-14.

7. Flammer J., Konieczka K., Bruno R.M., Virdis A., Flammer A.J., Taddei S. The eye and the heart. Eur Heart J 2013; 34(17): 1270-1278. doi: 10.1093/eurheartj/eht023.

8. Flammer J. Glaukom. 3 überarbeitete Auflage ed. Hans Huber Verlag: Bern; 2009.

9. Flammer J., Mozaffarieh M., Bebie H. Basic Sciences in Ophthalmology - Physics and Chemistry. Heidelberg: Springer, 2013. doi: 10.1007/978-3-642-32261-7.

10. Mozaffarieh M., Flammer J. Pocket Reference to Ocular Blood Flow and Glaucomatous Optic Neuropathy. Heidelberg: Springer, 2009. doi: 10.1007/978-3-540-69443-4.

11. Flammer J. The vascular concept of glaucoma. Surv Ophthalmol 1994; 38(Suppl): S3-S6.

12. Flammer J., Pache M., Resink T. Vasospasm, its role in the pathogenesis of diseases with particular reference to the eye. Prog Retin Eye Res 2001; 20(3): 319-349. doi: 10.1016/S1350-9462(00)00028-8.

13. Lekakis J., Abraham P., Balbarini A., Blann A., Boulanger C.M., Cockcroft J., Cosentino F., Deanfield J., Gallino A., Ikonomidis I., Kremastinos D., Landmesser U., Protogerou A., Stefanadis C., Tousoulis D., Vassalli G., Vink H., Werner N., Wilkinson I., Vlacho-poulos C. Methods for evaluating endothelial function: a position statement from the European Society of Cardiology Working Group on Peripheral Circulation. Eur J Cardiovasc Prev R 2011; 18(6): 775-789. doi: 10.1177/1741826711398179.

14. Camici P.G., Crea F. Coronary microvascular dysfunction. New Engl J Med 2007; 356(8): 830-840. doi: 10.1056/NEJMra 061889.

15. Delaney Y., Walshe T.E., O’Brien C. Vasospasm in glaucoma: clinical and laboratory aspects. Optometry Vision Sci 2006; 83(7): 406-414. doi: 10.1097/01.opx.0000225877.13217.01.

16. Choi J., Jeong J., Cho H.S., Kook M.S. Effect of nocturnal blood pressure reduction on circadian fluctuation of mean ocular perfusion pressure: a risk factor for normal tension glaucoma. Invest Ophthalmol Vis Sci 2006; 47(3): 831-836. doi: 10.1167/iovs.05-1053.

17. Choi J., Kim K.H., Jeong J., Cho H.S., Lee C.H., Kook M.S. Circadian fluctuation of mean ocular perfusion pressure is a consistent risk factor for normal-tension glaucoma. Invest Ophthalmol Vis Sci 2007; 48(1): 104-111. doi: 10.1167/iovs.06-0615.

18. Choi J., Lee J.R., Lee Y., Lee K.S., Na J.H., Han S., Kook M.S. Relationship between 24-hour mean ocular perfusion pressure fluctuation and rate of paracentral visual field progression in normal-tension glaucoma. Invest Ophthalmol Vis Sci 2013; 54(9): 6150-6157. doi: 10.1167/iovs.13-12093.

19. Yeghiazaryan K., Flammer J., Golubnitschaja O. Predictive molecular profiling in blood of healthy vasospastic individuals: clue to targeted prevention as personalised medicine to effective costs. EPMA J 2010; 1(2): 263-272. doi: 10.1007/s13167-010-0032-3.

20. Mozaffarieh M., Konieczka K., Flammer J. Calcium channel blockers: their use in normal tension glaucoma. Expert Rev Ophthalmol 2010; 5(5): 9. doi: 10.1586/eop.10.54.

21. Golubnitschaja O., Yeghiazaryan K., Flammer J. In: Neurodegenerative Diseases: Integrative PPPM Approach as the Medicine of the Future. Mandel S., eds. Dordrecht: Springer; 2013. Glaucomatous optic neuropathy: risk assessment and potential targets for effective prevention and treatments tailored to the patient; pp. 187-201. doi: 10.1007/978-94-007-5866-7_9.